World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
89046
World Ranking
5646
National Ranking
154

Overview

Grant A. McArthur is affiliated with the Peter MacCallum Cancer Centre in Australia and has contributed extensively to research in medicine and molecular biology, with a particular focus on oncology.

Their research spans several subfields, including oncology, molecular biology, pulmonary and respiratory medicine, immunology, and economics and econometrics. The main thematic areas covered in their work are:

  • Melanoma and MAPK Pathways
  • Cancer Immunotherapy and Biomarkers
  • CAR-T Cell Therapy Research
  • Cutaneous Melanoma Detection and Management
  • Brain Metastases and Treatment
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics

Recent significant publications authored by or in collaboration with Grant A. McArthur include:

  • "Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial" (2020, The Lancet)
  • "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma" (2022, Zurich Open Repository and Archive, University of Zurich)
  • "CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer" (2020, Nature Communications)
  • "5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study" (2021, Clinical Cancer Research)
  • "CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory" (2021, Cancer Discovery)

The scientist frequently collaborates with other researchers, including Paolo A. Ascierto, Karen E. Sheppard, Shahneen Sandhu, Caroline Robert, and Georgina V. Long, reflecting a network of active partnerships in the cancer research community.

Grant A. McArthur's work is published predominantly in journals such as the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Annals of Oncology, European Journal of Cancer, and Cancers. These venues represent the central platforms for disseminating research findings in oncology and related biomedical fields.

Their research contributions are characterized by a multidisciplinary approach integrating immunotherapy, molecular biology, and clinical oncology to address challenges in melanoma and other cancer treatments, demonstrating sustained engagement with emerging therapeutic modalities and cancer diagnostics.

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Inhibition of mutated, activated BRAF in metastatic melanoma.

    Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Oncogenic Signaling Pathways in The Cancer Genome Atlas

    Francisco Sanchez-Vega;Marco Mina;Joshua Armenia;Walid K. Chatila

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

    Ramin Nazarian;Hubing Shi;Qi Wang;Xiangju Kong

  • Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

    James Larkin;Paolo A. Ascierto;Brigitte Dréno;Victoria Atkinson

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

    Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang

  • Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

    Jessie Villanueva;Adina Vultur;John T. Lee;Rajasekharan Somasundaram

  • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

    Fei Su;Amaya Viros;Carla Milagre;Kerstin Trunzer

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

    Paolo A Ascierto;Grant A McArthur;Grant A McArthur;Brigitte Dréno;Victoria Atkinson

  • Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

    Georgina V Long;Victoria Atkinson;Serigne Lo;Shahneen Sandhu

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

    Danny Rischin;Richard J. Young;Richard Fisher;Stephen B. Fox

  • mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF.

    Katherine M. Hannan;Yves Brandenburger;Anna Jenkins;Kerith Sharkey

Frequent Co-Authors

Carleen Cullinane
Carleen Cullinane Peter MacCallum Cancer Centre
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Richard B. Pearson
Richard B. Pearson Peter MacCallum Cancer Centre
Ross D. Hannan
Ross D. Hannan Australian National University
Rodney J. Hicks
Rodney J. Hicks Peter MacCallum Cancer Centre
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Georgina V. Long
Georgina V. Long University of Sydney
Alexander Dobrovic
Alexander Dobrovic University of Melbourne
Keith T. Flaherty
Keith T. Flaherty Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in health sciences but not ready to pursue a full medical degree, there are several affordable online pathways to consider. Entry-level careers, such as medical billing and coding, provide vital support services and often require only certification. You can explore the cheapest medical coding certification online to jumpstart your journey in the healthcare field.

If you’re aiming for clinical roles, nursing offers both flexibility and strong job prospects. Numerous programs offer remote study options, including cheapest online nurse practitioner programs for those seeking advanced practice positions. For those just starting, consider the cheapest online bsn programs to qualify for RN licensure and entry-level nursing roles.

Looking to advance further in nursing leadership or research? Accredited online phd nursing programs can help you specialize and move into academic or high-level administrative careers. These varied options make it possible to launch or advance a healthcare career with flexibility and lower costs.

Best Scientists Citing Grant A. McArthur

Trending Scientists

Recently Published Articles